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Inducedpluripotent stemcells (iPSCs) are apromising
melanocyte source as they propagate indefinitely and
can be established frompatients. However, the in vivo
functions of human iPSC-derived melanocytes
(hiMels) remain unknown. Here, we generated hiMels
from vitiligo patients using a three-dimensional sys-
tem with enhanced differentiation efficiency, which
showed characteristics of human epidermal melano-
cytes with high sequence similarity and involved
in multiple vitiligo-associated signaling pathways. A
modified hair follicle reconstitution assay in vivo
showed that MITF+PAX3+TYRP1+ hiMels were local-
ized in the mouse hair bulb and epidermis and pro-
duced melanin up to 7 weeks after transplantation,
whereas MITF+PAX3+TYRP1 hiMelanocyte stem
cells integrated into the bulge-subbulge regions.
Overall, these data demonstrate the long-term func-
tions of hiMels in vivo to reconstitute pigmented hair
follicles and to integrate into normal regions for both
mature melanocytes and melanocyte stem cells,
providing an alternative source of personalized
cellular therapy for depigmentation.
INTRODUCTION
Melanocytes are derived from the neural crest and are the only
cell type producing melanin that protects skin cells against dam-
age from ultraviolet radiation. Consequently, the absence of
functional melanocytes leads to depigmentation disorders
such as vitiligo. The estimated worldwide prevalence of vitiligo
is 0.5%–1% (Ezzedine et al., 2015) and nearly 70%–80% of pa-
tients present with the condition before 30 years of age (Sehgal
and Srivastava, 2007). The quality of life of patients with vitiligo is
negatively affected because of the amelanotic skin (Hedayat
et al., 2016; Lilly et al., 2013; Pasxca et al., 2015), resulting inThis is an open access article under the CC BY-Nvarious psychological problems such as stress, embarrassment,
anxiety, and effects of stigma. As a result, some patients with
vitiligo have low self-esteem and experience social isolation
(Ezzedine et al., 2015; Picardo et al., 2015).
Various types of interventions have been developed to achieve
repigmentation of vitiligo, including a number of dermatosurgery
techniques such as suction blister grafting, split-thickness skin
grafting, punch grafting, follicular grafting, and melanocyte
transplantation (Rusfianti and Wirohadidjodjo, 2006). Surgical
therapies can be effective for patients with stable symptoms
(Barman et al., 2004; Linthorst Homan et al., 2012; Wind et al.,
2011). However, suction blister grafts and other types of tissue
grafting may lead to the precipitation of new areas of vitiligo at
donor sites due to the Koebner phenomenon (Whitton et al.,
2015). By contrast, melanocyte transplantation is a promising
therapy that is less frequently associated with adverse events
and provides superior cosmetic results for patients (Mulekar
and Isedeh, 2013).
Melanocytes can be isolated directly from the epidermis;
however, the restricted quantity and poor proliferative capability
have limited their application in cellular transplantation. There-
fore, it is still a challenge to obtain large quantities of autologous
melanocytes to treat patients with extensive lesions. Aside from
the epidermis, there are some other potential sources for mela-
nocytes generation, such as melanocyte stem cells and melano-
blasts (Cook et al., 2005; Goldstein et al., 2015), dermal stem
cells (Kumar et al., 2016b; Li et al., 2010), hair follicle stem cells
(Kumar et al., 2016a), stem cells of the hair follicle outer root
sheath (Schneider et al., 2014), embryonic neural crest stem
cells (Shakhova and Sommer, 2015), and embryonic stem cells
(ESCs) (Fang et al., 2006). Additionally, functional melanocytes
can also be induced from fibroblasts and keratinocytes by direct
reprogramming (Fehrenbach et al., 2016; Kazantseva et al.,
2016; Yang et al., 2014). Compared with these sources, induced
pluripotent stem cells (iPSCs) have significant advantages that
make them ideal for generating patients’ autologous melano-
cytes. Owing to their unlimited proliferation potential, iPSCs
could provide a large quantity ofmelanocytes;moreover, sample
collection is minimally invasive or completely noninvasive.Cell Reports 27, 455–466, April 9, 2019 ª 2019 The Author(s). 455
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Establishment of iPSCs from Patient Fibroblasts
(A) Morphology of dermal fibroblasts derived from a white patch of a patient with vitiligo (N5).
(B) Morphology of induced pluripotent stem cell (iPSC) lines (JSDV-5) of patient N5.
(C) Alkaline phosphatase staining results.
(D) qPCR results showing the expression of human embryonic stem cell (hESC) marker genes in human dermal fibroblasts (HDF), Jiangsu dermal vitiligo (JSDV)
cells (from patients N2, N5, and N10), and NiPSCs (iPSCs from healthy controls). Bars represent the relative quantity normalized to GAPDH (mean ± SD)
calculated from each iPSC clone at three different passages.
(E) Immunostaining for hESC markers.
(legend continued on next page)
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Another advantage of the application of iPSCs is fewer ethical
concerns compared to the use of ESCs. More importantly,
because genetically compatible iPSCs can be established from
individual patients, drug screening could be performed within a
personalized system to determine the most appropriate medical
treatments for each of the affected individuals in the near future.
Previous studies indicated that iPSCs can be differentiated
toward the melanocyte lineage (Jones et al., 2013; Nissan
et al., 2011; Ohta et al., 2011), and these human iPSC-derived
melanocytes (hiMels) could express characteristic melanocytic
markers, generate melanosomes, and integrate appropriately
into the reconstructed epidermis in vitro. However, the in vivo
functions and the hair follicle and epidermis reconstitution capa-
bility of hiMels have not been confirmed.
Accordingly, in this study we established iPSC lines from
patients with vitiligo and generated hiMels using a three-
dimensional (3D) differentiation system. Moreover, to explore
the potential pathogenesis of vitiligo we performed RNA
sequencing and a bioinformatics assay to identify the significant
pathways enriched in patient iMels. Finally, to confirm the in vivo
functions of hiMels, we modified the conventional hair follicle
reconstitution assay and transplanted the cells into immunodefi-
cient mice.
RESULTS
Establishment of Patient-Specific iPSCs
Skin biopsies were performed in patients with vitiligo (Fig-
ure S1A). Histological examinations, including hematoxylin and
eosin, 3,4-L-dihydroxyphenylalanine (L-DOPA), and Masson-
Fontana staining, showed that melanocytes were absent in
depigmented regions but were still present in the adjacent
normal skin (Figures S1B–S1D). The expression levels of genes
typical for mature melanocytes, such as TYR, TYRP1, and
DCT, were significantly lower in the white lesion area compared
with those in healthy skin (Figure S1E).
Patient iPSC lines (Jiangsu dermal vitiligo; JSDV) were estab-
lished from dermal fibroblasts (Figure 1A) isolated from depig-
mented regions using Yamanaka factors (OCT3/4, SOX2,
KLF4, and c-MYC). Non-integrating reprogramming was also
conducted using RNA-based protocols (Figure S1K). These pa-
tients’ clones presented morphological characteristics that were
largely similar to those of human ESCs (Figures 1B, S1F, and
S1L) and showed high levels of alkaline phosphatase (AP; Fig-
ures 1C and S1G). The expression levels of ESC-specific marker
genes such as OCT4, SOX2, NANOG, LIN28A, DNMT3B, REX1,
and GDF3 were also comparable to those of iPSCs established
from healthy individuals (Figure 1D). Specific multipotential
markers, including NANOG, SSEA4, OCT4, and TRA-1-60,
were also detectable by immunofluorescence staining (Figures
1E and S1M). When transplanted to mice with severe combined(F) Teratoma formation assay: respiratory epithelium (endoderm), cartilage (mesod
by injection of a clone of JSDV-5 cells into the testis of a non-obese diabetic sev
(G) Bisulfite genomic sequencing of the promoter regions of OCT4. Open a
clone JSDV-5).
(H) Chromosome analysis (clone JSDV-5). Results are representative of at least
Scale bars: 200 mm (A–C) and 100 mm (E and F). See also Figure S1.immunodeficiency, JSDV cells showed multipotential to form
teratomas that comprised tissues of three germ layers, including
the gut epithelium, muscle, cartilage tissue, neural tissue, and
pigment cells (Figures 1F, S1H, S1N, and S1O). Bisulfite
genomic sequencing analysis showed that the OCT4 promoter
was highly demethylated in JSDV cells whereas it was hyperme-
thylated in parental dermal fibroblasts, further verifying the
reprogramming of fibroblasts (Figures 1G and S1I). Additionally,
these cell lines had a normal karyotype after dozens of passages
(Figures 1H and S1J). Overall, these data confirmed the success-
ful establishment of iPSC lines from vitiligo patients with the
expected characteristics of ESCs.
Suspensive System for Melanocyte Differentiation
An embryoid body (EB)-based protocol was used to generate
patient iMels; however, the differentiation efficiency of the con-
ventional method (Ohta et al., 2011) was not satisfactory. In the
conventional two-dimensional (2D) culture system, the majority
of cells maintained an epithelial shape and were not differenti-
ated into melanocytes (Figures S2A–S2C). To reduce the ratio
of epithelium-like cells and improve the differentiation efficiency,
we optimized the conventional method and established a sus-
pensive system (Figure 2A). First, single-cell suspensions (Fig-
ure 2B) were prepared to generate uniform EBs (Figure 2C) using
a 3D micro-culture pattern. After 5–10 days of culture, enlarged
EBs (Figure 2D) were transferred into melanocyte differentiation
medium on ultra-low attachment plates and suspensive induc-
tion was initiated. Two weeks later, differentiated EBs (Figure 2E)
were plated onto fibronectin-coated plates. Large quantities of
dendritic-like cells with high proliferative ability could be
observed thereafter, whereas epithelium-like cells were rarely
found (Figure 2F). Single cells were dissociated and passaged
at week 3, which usually showed a typical dendritic morphology
at weeks 5–6 after differentiation (Figure 2G). High proliferative
activity was maintained even after several rounds of freezing
and thawing. In addition, the pigmentation of the cell pellet grad-
ually darkened throughout culture, which also usually became
remarkable by weeks 5–6 (Figure 2H). Thus, hiMels were suc-
cessfully generated using this suspensive system and the
same protocol was validated with multiple iPSC lines from other
vitiligo patients and healthy individuals (Figure S3).
To test whether this differentiation system was superior to the
conventional system, the gene expression levels of melanocytic
stem and/or progenitor markers were detected. By the end of
week 2 of the differentiation process, the levels of PAX3, MITF,
and SOX10 were 8, 3, and 18 times higher in this system than
those in the 2D culture, respectively (p < 0.05; Figure 2I; Table
S1). Additionally, the percentage of immunostained PAX3+ cells,
a marker of melanocyte stem and/or progenitor cells, was calcu-
lated as an index of the differentiation efficiency (Figure 2J). In
the 3D system, the percentage was approximately double thaterm), and pigment (ectoderm) cells found in a representative teratoma induced
ere combined immunodeficiency (NOD-SCID) mouse.
nd closed circles indicate demethylated and methylated CpG site (CpGs;
three independent experiments.
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Figure 2. Suspension Culture for Differentia-
tion into iMelanocytes
(A) Flow chart of suspensive differentiation.
(B) Single-cell suspension of iPSCs on Elplasia
plates.
(C) Embryoid bodies (EBs) cultured at day 1.
(D) EBs cultured at day 10.
(E) Differentiated EBs in the suspension system at
week 2.
(F) Large number of dendritic-like cells in the pe-
ripheral area of EBs on fibronectin-coated plates at
week 3.
(G) Split cells displayed the typical morphology of
melanocytes at week 5.
(H) Pigmentation of cell pellets at weeks 0 (a), 3 (b), 4
(c), and 5 (d), respectively.
(I) Comparison of gene expression of PAX3, MITF,
and SOX10 in the 2D and 3D culture systems at
week 2 of differentiation. Bars represent the relative
quantity normalized to that of GAPDH (mean ± SD)
calculated from five independent experiments. As-
terisks indicate statistically significant differences
(*p < 0.05, Student’s t tests).
(J) Immunostaining of differentiated EBs with PAX3
in the 2D and 3D systems (after attachment on
fibronectin-coated dishes) at week 2.
E, epithelial-like cells; M, iMelanocytes. Results are
representative of at least three independent exper-
iments. Scale bar: 200 mm. See also Figures S2 and
S3 and Table S1.detected in the 2D culture condition (79.5% ± 13.7% versus
38.1% ± 12.6%, p < 0.001; Table S1). Overall, these results sug-
gest that this 3D suspensive system considerably improved the
efficiency of the generation of iPSC-derived hiMels.
In Vitro Characteristics of Patient iMels
To investigate whether the patient iMels exhibited the character-
istics of normal human epidermal melanocytes (HEMs), we de-
tected the expression levels of melanocytic marker genes such
asMITF, PAX3, SOX10, KIT, TYR, TYRP1, and DCT, which were
found tobehighlyexpressed inpatient iMelswith levels equivalent
to those of iMels derived from healthy iPSCs and HEMs (Fig-
ure3A).Exogenousgeneswerenotdetectable (Figure3B).Patient
iMels were also immunocytochemically positive for TYRP1, TYR,
and MITF (Figure 3C), and exhibited positive results in L-DOPA
(Figure 3D) andMasson-Fontana (Figure 3E) staining. In addition,
we confirmed the generation ofmelanosomes,which are required
for theproduction ofmelanin, in the cytoplasmof patient iMels us-458 Cell Reports 27, 455–466, April 9, 2019ing transmission electron microscopy, and
found that these organelles were present
at a level similar to that of the positive con-
trol, HEMs (Figure 3F). To further assess
whether there are stem and/or progenitor
cells existing in the pool of hiMels, the
expression of stem and/or progenitor cell
markers was detected, which showed that
PAX3, MITF, and SOX10 were expressed
as early as the first week (Figures S2D and
S2E) and their levels increased steadily inthe process of differentiation (Figure S2D). When hiMels became
fully mature at week 7, their expression levels of PAX3 andMITF
were still much higher than those in HEMs (Figure S2D). Taken
together, these data demonstrate that patient iPSCs could differ-
entiate into functional melanocytes that share in vitro characteris-
tics and functions with HEMs and express higher levels of stem
and/or progenitor cell-related genes than HEMs.
Transcriptome Characteristics Based on RNA
Sequencing
Next, to better understand the genetic basis of vitiligo, we per-
formed RNA sequencing with iPSCs, hiMels, and HEMs. Anal-
ysis of differentially expressed genes between melanocytes
and iPSCs indicated that patient iMels showed similar transcrip-
tome characteristics to HEMs (Figure 4A) and their melanocytic
genes were comparably expressed (Figure 4B). There were
7,745 genes commonly expressed between these two types of
melanocytes, which accounted for 93.3% of the genes reliably
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Figure 3. Characterization of iMelanocytes
In Vitro
(A) qPCR analysis showed that ViMels (patient
iPSC-derived melanocytes) and NiMels (healthy
iPSC-derived melanocytes) expressed melanocytic
marker genes at levels comparable to those of
normal HEMs. Bars represent the relative quantity
normalized toGAPDH (mean ± SD), calculated from
four independent experiments.
(B) qPCR analysis showing that the exogenous
Yamanaka factors were silenced in both JSDV cells
and ViMels, whereas c-MYC was expressed at low
levels in both ViMels and HEMs.
(C) Immunostaining analysis of ViMels and NiMels
using antibodies against melanocyte-specific pro-
teins. NC, negative control.
(D) Positive L-DOPA staining of ViMels.
(E) Masson-Fontana staining of ViMels.
(F) Transmission electron microscopy image of
mature melanosomes (arrows) in the cytoplasm of
ViMels. Results are representative of at least three
independent experiments.
Scale bar: 200 mm (C) and 50 mm (D and E). See also
Figure S2.detected in HEMs (Figure 4C). Moreover, the gene expression
levels were highly correlated between patient iMels and HEMs
(r = 0.91) and genes involved in melanogenesis such as MITF,
SOX10,DCT, PEML, TYRP1, and TYRwere significantly upregu-
lated in patient iMels (Figure 4D).
To assess the differences between patient iMels and HEMs
and explore significant pathways related to vitiligo, their differen-
tially expressed genes were analyzed through Ingenuity Pathway
Analysis (IPA). The results demonstrated the involvement of mul-
tiple canonical signaling pathways (Table 1). Interestingly, we
found some classic pathways that accordedwith reportedmech-
anisms of vitiligo, such as interferon (IFN) signaling (Figure S4)
(Bertolotti et al., 2014; Briggs et al., 2011; Yang et al., 2015).
Greater susceptibility to oxidative stress has been reported in
melanocytes from patients with vitiligo compared to those from
unaffected individuals, which contributes to melanocyte damage
in vitiligo (Jimbow et al., 2001; Maresca et al., 1997). We also
identified multiple pathways linked with the oxidative stressresponse in melanocytes, including oxida-
tive phosphorylation (Sahoo et al., 2017;
Spiegelman and Elcheva, 2017), PI3K-
AKT signaling (Kim et al., 2017; Shin et al.,
2014), and NRF-2 (Shin et al., 2014). There-
fore, the RNA sequencing data not only
indicate the high similarity in transcriptome
characteristics between patient iMels and
HEMs but also reveal multiple signaling
pathways involved in the pathogenesis of
vitiligo.
Reconstitution of Pigmented Hair
Follicles In Vivo
To confirm the in vivo functions of hiMels,
we adopted amodified hair follicle reconsti-tution assay (Figure S5A) (Yang et al., 2014). In brief, patient iMels
were injected into the back skin of nude mice, which were mixed
with epidermal aggregates and dermal fibroblasts isolated from
the skin of neonatal BALB/cmice. HEMsand human dermal fibro-
blasts were used as controls instead of hiMels. Two weeks later,
the grafts were harvested (Figure S5B) and pigmented hair folli-
cles were found in mice transplanted with patient iMels and
HEMs (Figures 5A and S5C), whereas white hairs were generated
in animals transplantedwith fibroblasts (Figure S5D). In the recon-
stituted tissue with hiMels, L-DOPA-positive melanocytes were
found in the hair bulb and epidermis (Figures 5B, S5E, and
S5G). Masson-Fontana staining, which reveals the pattern of
melanin distribution, showed that pigmentation was mainly local-
ized in the hair bulb, hair shafts, as well as in the reconstituted
epidermis (Figures 5C, S5F, and S5H). By contrast, massive
melanin was deposited in the surrounding connective tissue after
transplantation with HEMs, whereas only quite limited melanin
was located in the hair bulb (Figure S5I). Immunostaining showedCell Reports 27, 455–466, April 9, 2019 459
Figure 4. Molecular Similarity of iMelano-
cytes and Human Epidermal Melanocytes
(A) Heatmap of genes differentially expressed in
JSDV cells (patient iPSCs), NiPSCs, ViMels, NiMels,
and HEMs (HEM-1, neonatal; HEM-2, adult) accord-
ing to RNA sequencing (RNA-seq) analysis.
(B) Heatmap of genes involved in the differentiation of
melanocytes.
(C) Venn diagram showing that of the 8,304 reliably
detected genes in HEMs, 7,745 were also expressed
in ViMels.
(D) Scatterplots showing a high correlation of gene
expression levels in HEMs and ViMels (r = 0.91).
Melanocyticmarkers are indicated by colored circles.
See also Figure S4.that the hiMels localized in the hair blub and basal cell layer of the
reconstituted epidermis expressed the melanocytic markers
MITF, PAX3, and TYRP1 (Figures 5D, 5E, 5F, and S5J). To further
verify that thesemelanin-producing cells were human derived, we
used a specific antibody recognizing the human nucleus antigen
and found that the positive cells also expressed TYRP1 (Figures
5G and S5K). Thus, these results reveal that mature hiMels could460 Cell Reports 27, 455–466, April 9, 2019integrate into the hair bulb and epidermis of
the reconstituted skin and producemelanin.
Maintenance of Long-Term Function
Since the hiMels were shown to express
the melanocytic stem and/or progenitor
markers MITF and PAX3 in vivo, we next
evaluated whether these stem and/or pro-
genitor cells could integrate into the hair
bulge of the grafts and provide long-
term function maintenance. Indeed, cells
co-expressing MITF and PAX3 were not
only localized in the hair blub but also in
the bulge-subbulge region, which was pos-
itive for the hair follicle stem cell marker
KRT15 (Figure S6A). These human-origin
cells in the bulge area were negative for
TYRP1 expression (Figure 6A), suggesting
a stem and/or progenitor feature. Another
hair follicle stem cell marker, ITGA6, was
also successfully used to localize these
MITF+TYRP1 hiMels not only in the ana-
gen hair follicle (Figures 6B and S6B) but
also in catagen or telogen follicles (Fig-
ure 6C). To confirm whether these stem
and/or progenitor hiMels contribute to
long-term function maintenance, we modi-
fied and established another hair follicle
reconstitution assay using a chamber (Fig-
ure S6C) (Lichti et al., 2008). In this revised
model, newly formed hairs grew outward
(Figure S6D) and properly shed in the
telogen phase, which did not occur in
the previous model established through
hypodermal injection. Additionally, sincethe host mice (BALB/c Nude) still have partial immunity, which
is even strengthened as they age during the longer observation
period, it is not suitable for the long-term survival of hiMels.
Therefore, we used an anti-Asialo GM1 antibody which depletes
natural killer cells and a subset of monocyte and macrophages
in vivo (Habu et al., 1981; Kasai et al., 1980). With this method,
patient iMels were still clearly detectable in the anagen hair
Table 1. Patient iMels Associated Canonical Signaling Pathways
Pathways
-log(p
Value)
Overlap with
Dataset (%)
Cell cycle: G2/M DNA damage
checkpoint regulation
5.47 26/48 (54.2)
Oxidative phosphorylation 5.32 42/95 (44.2)
Phagosome maturation 5.31 51/123 (41.5)
Mitochondrial dysfunction 4.5 57/150 (38.0)
PI3K-AKT signaling 3.89 47/123 (38.2)
Cyclins and cell cycle regulation 3.71 32/76 (42.1)
Interferon signaling 3.48 16/30 (53.3)
NRF2-mediated oxidative stress response 3.09 61/181 (33.7)
Cell cycle control of chromosomal replication 2.9 22/51 (43.1)
Retinoic acid mediated apoptosis signaling 2.72 19/43 (44.2)
Antigen presentation pathway 2.56 15/32 (46.9)
mTOR signaling 1.96 59/193 (30.6)
Semaphorin signaling in neurons 1.47 16/44 (36.4)
UVA-induced MAPK signaling 1.4 31/99 (31.3)
Integrin signaling 1.37 55/191 (28.8)
See also Figure S4.follicles at week 7 after transplantation (Figures 6D, 6E, S6E, and
S6F) and the pigmentation was localized in the epidermis, hair
bulb, and hair shafts (Figure 6F). These results indicate that the
stem and/or progenitor hiMels in the hair bulge could provide
long-term maintenance even after a hair growth cycle.
Collectively, these results demonstrate that patient iMels were
functional in vivo and contributed to the reconstitution of the hair
follicle and epidermis. Mature hiMels integrated into the hair bulb
and basal cell layer and took part in the generation of pigmented
hair shafts and the epidermis. Meanwhile, the existing hair follicle
stem cells in the bulge region function as a niche for melanocyte
stem cells and should support and provide the long-term func-
tion maintenance of hiMels.
DISCUSSION
A 3D suspensive culture system has been shown to provide a
more appropriate niche environment and to better mimic the nat-
ural cellular organization and function in vivo than conventional
2D culture and has, thus, been widely applied for iPSCs differen-
tiation and organoid generation (Haraguchi et al., 2015; Jo et al.,
2016; Lancaster et al., 2013; Lee et al., 2018; Muguruma et al.,
2015; Pasxca et al., 2015). In this study, we established a suspen-
sive system for the generation of iPSC-derived hiMels, which
reduced the percentage of epithelium-like cells and signifi-
cantly improved the differentiation efficiency compared to the
conventional method. These improved effects are considered
to be related to the better proliferative capability of hiMels in a
3D suspensive system, which inhibited the growth of epithe-
lium-like cells. Moreover, since epithelium-like cells in a flat
culture condition proliferate quickly, which requires more flat
spaces to be available, usually no more than 10 EBs can be im-
planted per well on a six-well plate at the beginning of differenti-
ation. By contrast, we were able to implant double the number ofEBs in the same cultural unit using the suspensive system
(Table S1).
It has long been difficult to evaluate the in vivo function of
human melanocytes because the xeno microenvironment is
inappropriate for the survival of these cells. Recently, Kawa-
kami et al. (2018) transplanted human iPSC-derived melano-
cytes into the skin regions. However, these cells were not
localized in the normal sites for mature melanocytes, and the
observation duration was quite limited. Here, we adopted and
modified a hair follicle reconstitution assay (Yang et al., 2014)
to create a better microenvironment for the survival of hiMels,
and successfully reconstituted pigmented hair follicles and
epidermis. In the grafts, mature hiMels were localized in the
hair bulb and basal cell layer, the normal sites for mature mela-
nocytes in humans (Tobin, 2011). Moreover, Masson-Fontana
staining indicated that melanin was also distributed in the hair
shafts, indicating the melanin transportation from hiMels to
mouse keratinocytes.
Follicular pigmentation is considered to be a result of struc-
tural and functional interactions involving melanocytes, matrix
keratinocytes, and dermal papilla fibroblasts (Cichorek et al.,
2013). The process of hair pigmentation also involves the mela-
nogenic activity of follicular melanocytes, transfer of melanin
granules into keratinocytes, and formation of pigmented hair
shafts (Slominski et al., 2005). Thus, this work suggests that
mature hiMels can interact with mouse cells, produce and trans-
fer melanin to the surrounding keratinocytes, and eventually
generate pigmented hair follicles and hair shafts.
However, the initial hair follicles reconstituted in the grafts will
undergo a growth cycle and these mature hiMels will turnover
with time. If there are stem and/or progenitor cells existing in
the pool of hiMels, they would allow for the sustainable regener-
ation of melanin in new hair cycles. As expected, human-derived
MITF+PAX3+TYRP1 stem and/or progenitors iMels were
co-localized with hair follicle stem cells (marked with KRT15
and ITGA6) in the bulge-subbulge region, in line with the results
of previous studies (Gleason et al., 2008; Nishimura, 2011; Nish-
imura et al., 2005; Osawa et al., 2005). At week 7 after transplan-
tation, mature hiMels were still clearly detectable in the bulb of
anagen hairs (identified by immunostaining, DOPA, and Mas-
son-Fontana staining). Thus, these results demonstrate that
hair follicle stem cells localized in the bulge region provide a
functional niche for melanocyte stem cells (Tanimura et al.,
2011). To the best of our knowledge, these data demonstrate
the longest survival and function maintenance of iPSC-derived
melanocytes in vivo, confirming their hair follicle and epidermis
reconstitution capacity. Moreover, this work represents the
best record involving xenografts of human melanocyte trans-
plantation into nude mice.
For humans, melanocytes in the hair follicles share many com-
mon characteristics with those in the epidermis, and they are
closely linked with each other. The process of melanin transport
from follicular melanocytes to the neighboring keratinocytes in
the growing hair shaft is similar to the epidermal phagocytosis
of melanosomes in keratinocytes (Cichorek et al., 2013). Addi-
tionally, the most common presentation of repigmentation in viti-
ligo after treatment is a perifollicular pattern, which is mainly
dependent on follicular melanocytes (Birlea et al., 2017).Cell Reports 27, 455–466, April 9, 2019 461
Figure 5. Reconstitution of Pigmented Hair
Follicles with Patient iMelanocytes In Vivo
(A) Pigmented hair follicles (arrowheads) were
formed in nude mice injected with patient iMels.
(B) Patient iMels (arrows) were mainly localized in
the hair bulb as shown by L-DOPA staining.
(C) Distribution of melanin in the hair bulb and hair
shafts as shown by Masson-Fontana staining.
Arrows, melanin in the hair bulb; arrowheads,
melanin in the hair shafts.
(D) Immunostaining of reconstituted hair follicles
with melanocytic markers, MITF (green) and TYRP1
(purple). Arrows:MITF+TYRP1+ cells in the hair bulb.
(E) Immunostaining of reconstituted hair follicles
with melanocytic markers, MITF (green) and hPAX3
(red). Arrows: MITF+hPAX3+ cells in the hair bulb.
(F) Immunostaining showing that cells expressing
MITF (green) and hTYRP1 (red) were co-localized
with the basal cell layer, markedwith ITGA6 (purple).
(G) Immunofluorescence staining showing the
co-localization of signals from antibodies recog-
nizing human nuclei (hNuc, green) and the mela-
nocytic marker TYRP1 (red) in the hair bulb. Results
are representative of at least three independent
experiments.
Scale bars: 200 mm (B, C, and G), 100 mm (D and E),
and 50 mm (F). See also Figure S5.Therefore, the model developed in our study provides a tool to
reveal the potential functions of hiMels after transplantation.
Interestingly, we also found that the integration efficiency of
patient iMels into mouse hair follicles was higher than that of
HEMs according to multiple experiments in different individuals.
Melanin produced by hiMels wasmainly localized in the hair bulb
and hair shafts, whereas massive melanin deposits were de-
tected in the connective tissue around the hair follicles after
HEM injection, indicating that most of the HEMs failed to survive
in the grafts. The different outcome after transplantation of
hiMels and HEMs might be associated with two key factors
that are tightly coordinated: proliferation and differentiation. Pre-
mature differentiation can result in a depletion of proliferating
cells and organ failure (Lee et al., 2013). In our study, we typically
transplanted hiMels at about week 5 of differentiation, which
maintained a high level of proliferative activity but were not as462 Cell Reports 27, 455–466, April 9, 2019mature as the HEMs (the color of the cell
pellet was usually dark gray and not as
black as that of the HEM pellet). By
contrast, the HEMs used in our study
were fully mature and their proliferative
ability decreased gradually with the dura-
tion of culture. Thus, our results support
the importance of maintaining the balance
between proliferation and differentiation
for organ formation and tissue mainte-
nance, which is especially critical in tissues
that undergo rapid turnover such as the
skin (Lee et al., 2013). Additionally, we
found a considerable number of hiMels
that were DOPA positive but Masson-Fontana negative (Figures S5G and S5H) or showed MITF-
positive but TYRP1 negative (Figures 6B and 6C) in the dermis,
suggesting that hiMels are heterogeneous populations with
different degrees of maturation and that stem and/or progenitor
cells might contribute to the progression of hiMels in vivo.
Vitiligo is featured by the loss of functional melanocytes, and
various hypotheses have been suggested to explain this loss.
With the availability of patient iPSC-derived iMels, the melano-
genic process and melanocyte development ex vivo may serve
as a model to discover the intrinsic mechanism of melanocyte
loss-related diseases. Although this model will not resolve all
of the current challenges in understanding the complete mecha-
nism, the first signs of the dawn are beginning to appear.
There are several vitiligo-related signal pathways and net-
works, which accord with the hypotheses of mechanisms
proposed during the past few decades in this field. Gaining a
Figure 6. Maintenance of the Long-Term
Function of iMelanocytes In Vivo
(A–C) Reconstituted tissue collected at week 2 after
transplantation.
(A) Immunostaining of hair follicles with the human
nuclei markers (hNuc, green), hTYRP1 (red), and hair
follicle stem cell marker KRT15 (purple). The bulge
areas are demarcated by brackets. Arrowheads:
hNuc+/hTYRP1 cells in the bulge area of an anagen
hair follicle.
(B) Immunostaining of hair follicles with the melano-
cytic markers MITF (green), hTYRP1 (red), and hair
follicle stem cell marker ITGA6 (purple). The bulge
areas are demarcated by brackets. Arrow, hTYRP1+
cells in the hair bulb; arrowheads, MITF+/hTYRP1
cells in the bulge region of an anagen hair follicle.
(C) Immunostaining showing MITF+/hTYRP1 cells
co-localized with ITGA6 in the bulge region of a
catagen or telogen hair follicle.
(D–F) Reconstituted tissue collected at week 7 after
transplantation.
(D) Immunostaining of reconstituted tissue after
transplantation with MITF (green) and hTYRP1 (red).
(a) Arrows, MITF+/hTYRP1+ cells in the hair bulb; (b)
arrowhead, MITF+/hTYRP1+ cells in the epidermis.
(E) hiMels were localized in an anagen hair bulb as
determined by L-DOPA staining.
(F) Distribution of melanin in the reconstituted
epidermis (a), hair bulb (b), and hair shafts (c) deter-
mined by Masson-Fontana staining. Results are
representative of at least three independent experi-
ments.
Scale bars: 100 mm (A, Ba, E, Fa, and Fc) and 50 mm
(Bb, Bc, C, D, and Fb). See also Figure S6.comprehensive understanding and integration of these hypothe-
ses will undoubtedly lead to new concepts and treatment
solutions. The association between IFN and melanocytes as
well as vitiligo has been reported upon in a large number of
studies. IFN-g showed strong adverse effects on cultured human
melanocytes, such as melanogenesis inhibition, viability loss,
apoptosis, cell cycle arrest, and senescence (Wang et al.,
2014; Yang et al., 2015). Moreover, the development of vitiligo
has been reported in some patients after treatment with IFN ther-
apy for primary diseases such as viral hepatitis (Anbar et al.,
2008; Hamadah et al., 2010), melanoma (Daneshpazhooh
et al., 2006; Gogas et al., 2006; Richards et al., 1992), and mul-
tiple sclerosis (Coghe et al., 2018; Kocer et al., 2009). However,
there is also direct evidence of this association based on the
abnormal expression of IFN in patients with vitiligo. The mRNA
and protein expression levels of IFN-g or type I IFN were shown
to be increased in the blood samples of patients with active viti-
ligo compared with those of patients with stable disease or
healthy controls (Briggs et al., 2011; Dwivedi et al., 2013). TheIFN-specific signature or IFN-producing
cells were also elevated in the blood or
skin lesions (Abdallah et al., 2018; Badri
et al., 1993; Bertolotti et al., 2014; Rashighi
et al., 2014; Yang et al., 2015). Overall, there
appears to be a strong association betweenIFN andmelanocytes destruction as well as vitiligo development.
In the present study, RNA sequencing also showed the involve-
ment of IFN signaling pathway and upregulation of IFN-g
receptors in patient iMels. Combined with other IPA results, we
assumed that the abnormal response of patient melanocytes
to IFN (due to upregulation of the receptor) and/or to oxidative
stress leads to the autoimmune-mediated melanocyte destruc-
tion and vitiligo progression (Richmond et al., 2013). However,
given the limited sample size and the fact that the same mecha-
nisms might not apply to all cases, the involvement of these
pathways in the pathogenesis of vitiligo will need to be verified
with larger samples in an effort toward identifying target mole-
cules for therapy.
There is particular concern for the safety of transplanted donor
cells for their clinical application. In our experiments, patient iMels
without exogenous genes ultimately underwent senescence after
continued culturing for several months. Tumorigenicity was also
not found in the grafts at week 7 after transplantation (tumors
are usually detectable at week 2 or 3 after transplantation ofCell Reports 27, 455–466, April 9, 2019 463
melanoma cell lines in nude mice; data not shown). These results
indicated a lack of tumorigenicity of iPSC-derived melanocytes,
which will pave the way for their potential clinical application in
cellular transplantation therapy. Nevertheless,modified protocols
for generating clinical-grade melanocytes are necessary, and the
lack of tumorigenicity must also be confirmed in more stringent
experiments in the future. Recently, autologous transplantation
of iPSC-derived retinal pigment epithelial cells was performed,
with no serious adverse event noted (Mandai et al., 2017). Mela-
nocytes and retinal pigment epithelial cells share many common
aspects, including their embryonic origin. Therefore, this clinical
study provides important information regarding the possibility
of iPSC-derived melanocytes in autologous transplantation
therapy.
In conclusion, we demonstrated that iPSCs of vitiligo patients
have the potential to differentiate into melanocytes, with func-
tionality observed both in vitro and in vivo. More significantly,
these hiMels possessed capacities of hair follicle and epidermis
reconstitution and long-term function maintenance. Thus, our
work provides a potential resource of cells for personalized
cellular therapy of patients with depigmentation. In addition,
our findings may provide insight into the pathogenesis of vitiligo.
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pMXs-hOCT3/4 Takahashi et al., 2007 Addgene Plasmid #17217
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pMXs-hKLF4 Takahashi et al., 2007 Addgene Plasmid #17219
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Information of Patients with VitiligoNumber Sex Age (y) Site
N2 Female 22 Thigh
N5 Male 45 Waist
N10 Female 36 ForeheadFibroblasts of Patients
Under the permission of the Ethical Review Board of Affiliated Hospital of Jiangsu University (October 2014), as well as after having
obtained necessary informed consent from all study subjects, freshly isolated skin specimens were obtained at the hospital. All
experimental protocols for skin samples were approved by the ethics committee of Affiliated Hospital of Jiangsu University.
Skin tissue was collected after nevus resection of patients with halo nevus. The depigmented part was manually cut into
smaller pieces and then transferred into 10-cm dishes. Culture medium consisting of DMEM/high glucose, 10% fetal bovine
serum, and 1% penicillin/streptomycin was then added. The dishes were placed in an incubator for 4-5 days so that the tissue
could adhere to the surface. Thereafter, half of the medium was replaced every 2 days. When 5 to 10 colonies comprising
50–100 cells formed, the medium was changed completely every 2 days. The fibroblasts were harvested when there were
enough cells and then passaged.
Patient iPSC Lines
Patient iPS cell lines (JSDV) were generated by retroviral transduction where the retroviral vectors were prepared through calcium
phosphate transfection of PlatE cells with pMX-vectors that harbored sequences encoding human OCT3/4, SOX2, KLF4, and
c-MYC(Takahashi et al., 2007). Briefly, the virus-containing supernatant from PlatE cells was used to transduce patients’ fibroblasts
(passage 3-5, 105 cells were seeded in eachwell of a 6-well plate) in the presence of 4 mg/mL of polybrene. Themediumwas replaced
12 h later and the fibroblasts were allowed to recover for 48 h. Thereafter, they were seeded at a density of 3-43 104/well in a 6-well
plate on mouse embryonic fibroblasts treated with mitomycin C. The culture medium used to maintain iPSCs contained DMEM/F12
supplementedwith 20%KSR, 13 non-essential amino acids solution, 4 ng/mL bFGF, 0.1mM2-Mercaptoethanol and 13GlutaMAX.
Colonies with typical iPSCs morphology were picked when they were large enough.
Non-integrating reprogramming was conducted using StemRNA-NM Reprogramming Kit. Briefly, fibroblasts were seeded at a
density of 23 104/well in 6-well plates coatedwith iMatrix-511 in fibroblast culturemedium. After 24 hours, themediumwas switched
to NutriStemTM XF/FF culture medium and NM-RNA cocktail was transfected using Lipofectamine RNAiMAXTM transfection
reagent. Four transfections were conducted and iPSC colonies were usually found on day 6-7.
Animal Studies
Male nude (BALB/c Nude) mice (5-7 weeks), NOD/SCIDmice (4-6 weeks), and neonatal BALB/cmice (1-2 days after birth) were used
in the experiments. All animal experiments were approved by the Laboratory Animal Management Committee of Jiangsu University
(UJS-LAER-201510601)
METHOD DETAILS
Teratoma Formation
Feeder-free iPSCswere harvested and suspended in DMEM/F12. One quarter of the cells from a confluent 100-mmdishwas injected
into the testis of one NOD/SCID mouse. Teratoma were collected typically in 2-3 months and paraffin-embedded tissue was
sectioned and stained with hematoxylin and eosin.
Uniform Embryoid Body Formation
iPSCsweremaintained in feeder-freecultureconditionwithmTeSR.Asingle-cell suspensionof iPSCswaspreparedwithACCUTASETM;
Approximately 53 105 cells were added to each well in an ElplasiaTM plate (24-well), and Y27632 was added to a final concentration of
10mM.AggreWell EBFormationMediumwasused.After 24h, theaggregateswerecollectedandcultured further inultra-lowattachment
plates for 5-10 days.
Conventional Differentiation System
iPSCs maintained under a feeder-free culture condition were treated with TrypLE Express to generate small aggregates. These
aggregates were cultured in ultra-low attachment plates with AggreWell EB Formation and 10 mM Y27632 was added in the first
24 hours. After 5-10 days, enlarged EBs were collected and plated on a fibronectin-coated plate for differentiation.Cell Reports 27, 455–466.e1–e5, April 9, 2019 e3
Suspension Differentiation System
EBs were collected and transferred to melanocyte differentiation medium (Fang et al., 2006) which contained conditioned medium
from L-Wnt3a cells (50%), low-glucose DMEM (30%), MCDB 201 medium (20%), 0.05 mM Dexamethasone, 1 3 insulin-transferrin-
selenium, 13 linoleic acid-bovine serumalbumin, 104ML-ascorbic acid, 50 ng/mLSCF, 100 nMEndothelial-3, 20 pMcholera toxin,
50 nM 12-O-tetradecanoyl-phorbel 13-acetate (TPA), and 4 ng/mL bFGF in ultra-low attachment plates. Half of the medium was
replaced every 2-3 days. After two weeks, differentiated EBs were collected and plated on a fibronectin-coated plate. Cells were
cultured for another 7 days and dissociated using TrypLE Express Enzyme and passaged. Differentiation medium with 0.5% FBS
was used, but without TPA. Since then, iMelanocytes were passaged every 3-4 days.
Hair Follicle Reconstitution Assay
Theprotocol for isolation of neonatalmouse skin cells refers to the previous one (Lichti et al., 2008). First, truncal skins from1-2-day-old
BALB/cmice, amouse strainwithout pigmentation, were removed and transferred into 0.25%cold trypsin in 10 cmdishes. Disheswith
floating skins were stored at 4C overnight in a refrigerator. Next day, they were transferred gently into a clean dish and epidermises
weremade to contact the dish and spread. Dermiseswere lifted up straight above the epidermises and transferred to a tube containing
cold fibroblasts medium (DMEM/high glucose, 10%FBS and 1%penicillin /streptomycin) for later preparation of fibroblasts. Edges of
epidermises were folded with forceps toward their centers, and each packet of epidermis was transferred to the dish containing cold
epidermis medium (DMEM/high glucose, 8% FBS, 1.2 mM CaCl2, and 1% penicillin /streptomycin).
Collected epidermises wereminced with scissors. The resulting suspension was triturated by pipetting up and downmore than ten
times, and then was transferred to a 50 mL conical tube. Cell suspension was centrifuged at 200 g for 5 minutes and the supernatant
including any floating stratum corneum pieces was carefully aspirated. Pellet in epidermis medium was resuspended and filtered
through a 100-mmcell strainer. The collected cells were centrifuged again at 200 g for 5minutes and pellet resuspendwas suspended
in epidermis medium. The total epidermal cell preparation included intrafollicular keratinocytes and hair follicle buds (aggregates).
The dermises were minced and incubated in 0.35% collagenase type I with agitation at 37C in a shaking incubator (100 rpm) for
40minutes. Then the digest was diluted with fivefold fibroblast medium and filtered through a 100-mmcell strainer. Filtrate was centri-
fuged at 300 g for 5minutes and resuspended with fibroblasts medium. Subsequently, centrifugation was conducted five to six times
(3 minutes for each time, low speed (50 g)) to remove most of hair follicles. Finally, it was centrifuged at 300 g (5 minutes) and resus-
pended with fibroblast medium.
Hair follicle reconstitution assays established by hypodermal injection were performed as described previously (Yang et al., 2014).
The fresh cell mixtures were injected in 5-7-week-old male nude (BALB/c Nude) mice with hiMels. For each injection, 13 106 BALB/c
neonatal dermal cells, 1 3 104 epidermal aggregates and 0.5 3 106 hiMels were used. In addition, 0.5 3 106 human fibroblasts and
normal HEMweremixed with mouse cells as controls instead of hiMels. At week 2, the reconstituted skin tissues were harvested and
embedded in OCT compound.
In hair follicle reconstitution assays established by the chamber method (Lichti et al., 2008), a portion of back skin was removed
with scissors to create a 1-cm diameter hole. Then the rim of chamber was inserted under the skin and was clipped to the chamber
with autoclips, to prevent the chamber from popping out of the hole. Cell suspension was ejected through the hole of the dome onto
the graft area using the Pipetman. 53 106 dermal cells, 53 104 epidermal aggregates and 2.53 106 hiMels were transplanted in one
chamber for each mouse. Chambers were removed 7 days after grafting. At different time points, the reconstituted tissues were
harvested and embedded in OCT compound.
Real-time PCR
Total RNA was isolated using TRIzol and reverse transcribed into cDNA using a RevertAid First Strand cDNA Synthesis Kit according
to the manufacturer’s instructions. Amplification was performed on a real-time PCR system (Applied Biosystems QuantStudio 3,
USA). The whole procedure was according to the manual of SYBR Premix Ex Taq kit. Gene expression levels were normalized to
that of GAPDH and were quantified based on the DCt method.
RNA Sequencing
Total RNA was extracted using TRIzol reagent following the manufacturer’s procedure. The libraries of ViMel-1, ViMel-2, JSDV-5,
HEM-1were sequenced using 150-bp paired-end sequencing on an Illumina HiSeq 4000 instrument. The libraries of the rest samples
were sequenced using 150-bp paired-end sequencing on an Illumina HiSeq X Ten instrument. All paired-end reads of each sample
were trimmed and quality filtered via fastp 0.18.0. HISAT2 2.1.0 (Kim et al., 2015)was used to map the filtered reads against the
human reference sequence (hg 38). Mapped reads were counted and then transcript abundance was measured in FPKM (fragments
per kilobase of transcript per million fragments mapped) units using StringTie (v1.3.4d)(Pertea et al., 2015)
Bioinformatics for RNA Sequencing Data
Differentially expressed (fold change of FPKM value > 2 or < 0.5) gene profiles between iPSCs and melanocytes, and genes involved
in the differentiation of melanocytes (Mort et al., 2015) were normalized (Z-score normalized FPKM values) for heatmap which was
generated using pheatmap package in R. K-means cluster was performed in Cluster 3.0(Eisen et al., 1998). Common genes ex-
pressed in patient iMel and HEM were selected for Venn diagram. Scatterplots were generated by using ggplot2 in R. Differentiallye4 Cell Reports 27, 455–466.e1–e5, April 9, 2019
expressed (fold change of FPKM value > 2 or < 0.5) gene profiles between patient iMels and HEM-1 were analyzed by Ingenuity
Pathway Analysis (IPA) to identify the most significant pathways and discover potential regulatory networks associated with
patient iMels.
Immunocytochemistry
Cells or frozen tissue samples were fixed with 4% paraformaldehyde for 15 minutes (4C), and then washed and permeabilized three
times with PBST (0.5% Tween20 in PBS) (5 minutes for each time, RT). Normal goat serumwas used as a blocking reagent to reduce
background for 1 hour (RT). After incubation with primary antibody overnight (4C), samples were subsequently incubated with the
second antibody for 1 hour (room temperature). Optical sections of the cells were observed under a Nikon-ECLIPSE Ti-S fluores-
cencemicroscope (Nikon, Japan). The dilution ratio for primary antibodies is as follows: OCT4 (Santa Cruz, 1:100), NANOG (Genetex,
1:200), TRA-1-60 (Millipore, 1:100), SSEA4 (DSHB, 1:100), TYR (Millipore, 1:100); TYRP1 (Millipore, 1:200); TYRP1 specific for human
(NSJ bioreagents, 1:200); MITF (Sigma-Aldrich, 1:200); SOX10 (Abcam, 1:250); PAX3(Atlas Antibodie,1:100); Anti-Nuclei antibody
specific for human (Millipore, 1:500); KRT15 (Millipore, 1:100); ITGA6 (Biolegend, 1:200). The dilution ratio for all the second anti-
bodies is 1:500.
L-DOPA Staining
Cells or tissue sections were fixed with 4% paraformaldehyde and incubated in a 0.1% solution of L-DOPA in PBS for 3-4 hours at
37C. The nuclei were stained with hematoxylin and sections were thoroughly dehydrated in absolute alcohol.
Masson-Fontana Staining
Masson-Fontana kit was used. Briefly, cells or tissue sections were fixed with 4% paraformaldehyde and then treated with ammo-
niacal silver nitrate solution in a closed jar for 40minutes at 56C. Samples were washedwell in ddH2O and treated with hypo solution
for 5 minutes. Then, samples were counterstained with neutral red stain for 5 minutes and rinsed in ddH2O. Finally, the preparations
were thoroughly dehydrated.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical and graphical data analyses were performed using Microsoft Excel and Prism 5 (Graphpad) software. Data are presented
as means ± SD. Student’s t tests was used to calculate P values where appropriate. p < 0.05 was considered to be significant.
DATA AND SOFTWARE AVAILABILITY
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